ERBB2 and breast carcinoma: Both the novel and established HER2 pathway gene signatures were predictive of response to neratinib in multivariate analysis using a pharmacogenomic breast cancer cell line model (Pearson R = 0.9, p < 1e−14 for both; see Supplemental Figure S2 in Additional file 3 for the original plots from the CellMinerCDB online portal).